Smithfield Trust Co. held its stake in shares of Evolent Health, Inc (NYSE:EVH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,000 shares of the technology company’s stock at the end of the second quarter. Smithfield Trust Co.’s holdings in Evolent Health were worth $101,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. US Bancorp DE raised its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after buying an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in shares of Evolent Health during the first quarter worth $126,000. Bank of Montreal Can raised its stake in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock worth $138,000 after buying an additional 6,077 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Evolent Health by 286.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock worth $150,000 after buying an additional 5,000 shares in the last quarter. Finally, IPG Investment Advisors LLC bought a new stake in shares of Evolent Health during the first quarter worth $206,000. Institutional investors and hedge funds own 73.16% of the company’s stock.

Shares of Evolent Health, Inc (EVH) opened at 18.15 on Thursday. Evolent Health, Inc has a 1-year low of $14.50 and a 1-year high of $27.50. The stock has a 50 day moving average price of $25.20 and a 200 day moving average price of $22.71. The stock’s market capitalization is $1.05 billion.

Evolent Health (NYSE:EVH) last issued its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The firm had revenue of $107.30 million during the quarter, compared to analysts’ expectations of $104.45 million. During the same quarter last year, the company posted ($0.20) earnings per share. The firm’s revenue was up 89.9% compared to the same quarter last year. Equities research analysts anticipate that Evolent Health, Inc will post ($0.42) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/smithfield-trust-co-has-101000-position-in-evolent-health-inc-nyseevh/1466927.html.

A number of equities research analysts have weighed in on EVH shares. BidaskClub lowered shares of Evolent Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Robert W. Baird set a $35.00 target price on shares of Evolent Health and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, May 3rd. Jefferies Group LLC reiterated a “buy” rating and set a $28.00 target price on shares of Evolent Health in a research note on Thursday, April 13th. Finally, TheStreet upgraded shares of Evolent Health from a “d” rating to a “c-” rating in a research note on Monday, May 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $29.90.

In other Evolent Health news, Director Cheryl Scott sold 5,477 shares of Evolent Health stock in a transaction on Friday, May 19th. The shares were sold at an average price of $23.51, for a total value of $128,764.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Frank J. Williams sold 114,865 shares of Evolent Health stock in a transaction on Friday, May 19th. The shares were sold at an average price of $24.30, for a total transaction of $2,791,219.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,153,967 shares of company stock valued at $253,648,377. 8.79% of the stock is currently owned by corporate insiders.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc (NYSE:EVH).

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.